Dosimetric Difference of Urinary Bladder and Rectum in Patients Undergoing Intracavitary Brachytherapy for Cervical Cancer under Procedural Sedation and General Anesthesia: A Survey at Bugando Cancer Center and Ocean Road Cancer Institute
Main Article Content
Abstract
Background: High-Dose-Rate Intracavitary Brachytherapy (HDR-ICBT) is a commonly employed treatment modality for cervical cancer, delivering a high dose of radiation directly to the tumor site while minimizing exposure to surrounding healthy tissues. Anaesthesia administration during HDR-ICBT varies, with some centres using Sedation (CS) and others employing General Anaesthesia (GA). Despite the widespread use of these anaesthesia techniques, their potential impact on dosimetric outcomes, particularly in the urinary bladder and rectum, remains an area of interest and investigation.
Objective: This study aimed to determine the dosimetric difference in the urinary bladder and rectum doses among cervical cancer patients undergoing HDR-ICBT under CS and GA. The study was conducted at Bugando Cancer Centre (BCC) and Ocean Road Cancer Institute (ORCI) to compare the dosimetric outcomes between the two anaesthesia techniques.
Methods: A total of 273 patients who underwent HDR-ICBT for cervical cancer were included in the study. Patients were divided into two groups based on the anaesthesia technique used during the procedure: 143 patients received GA, and 130 patients received CS. Dosimetric parameters of the urinary bladder and rectum doses were collected and analysed using descriptive statistics and the independent samples t-test.
Results: The findings demonstrated a statistically significant dosimetric difference in the mean urinary bladder dose between patients treated under GA and CS (p < 0.001). Patients under GA received a significantly lower mean urinary bladder dose compared to those under CS. However, no statistically significant difference was observed in the mean rectum dose between the two anaesthesia groups (p = 0.689).
Conclusion: The study reveals that the choice of anesthesia technique significantly impacts the urinary bladder dose during HDR-ICBT for cervical cancer. Patients receiving GA had a lower mean urinary bladder dose compared to those under CS. However, no significant dosimetric difference was observed in the mean rectum dose between the two anesthesia groups. These findings emphasize the importance of considering anesthesia techniques during treatment planning to optimize dosimetric outcomes and patient safety in HDR-ICBT. Further investigation and long-term follow-up are warranted to validate and expand upon these results. Collaboration between radiation oncologists and anesthesia teams is crucial to enhance treatment efficacy and minimize potential complications during HDR-ICBT for cervical cancer
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. WHO. Comprehensive Cervical Cancer Control. Geneva. 2014;366–78.
II. ICO/IARC Tanzania Human Papillomavirus and Related Cancers FS 2023 (2023-03-10). ICO/IARC Information Centre on HPV and Cervical Cancer (HPV Information Centre): Human Papillomavirus and Related Cancers in Tanzania. Summary Report. 2023, [http://www.who.int/hpvcentre]. 2013; 2014:1–10.
III. Sharma DN, Chaudhari P, Sharma S, Gupta L, Jagadesan P, Rath GK, et al. Comparison of high-dose-rate intracavitary brachytherapy dosimetry with and without anesthesia in patients with cervical carcinoma. J Appl Clin Med Phys. 2014; 15(2):60–6.
IV. Sharma S, Singh R, Sharma PK, Datta NR. A retrospective dosimetric study of brachytherapy in cervical cancer patients under general anesthesia versus conscious sedation. J Cancer Res Ther.2018;14(5):1007-12
V. Kumar D, Srinivasa GY, Gupta A, Rai B, Oinam AS, Bansal P. Comparative study to evaluate dosimetric differences in patients of locally advanced carcinoma cervix undergoing intracavitary brachytherapy under two different anaesthesia techniques : an audit from a tertiary cancer centre in India. Journal of the Egyptian National Cancer Institute; 2019;2:0–5.
VI. National Cancer Institute. Brachytherapy to Treat Cancer. NCI [Internet]. 2023;15–8. Available from: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/brachytherapy#:~:text=Brachytherapy is a type of internal radiation therapy in which,specific part of your body.
VII. Anker CJ,O'Donnell K, Boucher KM, Gaffney DK. Effect of brachytherapy technique and patients characteristics on cervical cancer implant dosimetry. Med Dosim. 2013 Winter;38(4):430-5.
VIII. Itami J, Murakami N, Watanabe M, Sekii S, Kasamatsu T, Kato S, et al. Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer. Front Oncol. 2022;11(January):1–8.
IX. Roessler B, Six LM, Gustorff B. Anaesthesia for brachytherapy. Curr Opin Anaesthesiol. United States; 2008 Aug;21(4):514–520.
X. Mousavi AS, Sharafi AA, Akbari F, Davenport D, Ghaffari H, Gholami S. A dosimetric comparison between intracavitary brachytherapy of cervical cancer patients under general anesthesia versus spinal anesthesia J Appl Clin Med Phys. 2015;16(3)5222
XI. Kim, J.Y.,Kim, J. H., Kim,Y.S., Ahn, S.D., Choi, E.K.,& Kim, S.S (2017).The effect of general anesthesia versus conscious sedation for intracavitary brachytherapy on dosimetric parameters and acute toxicity in patients with cervical cancer. Radiation Oncology Journal, 35(3), 201-208.
XII. Petit MS, Ackerman RS, Hanna MM,Chen L, Mhaskar RS, Fernandez DC, Patel SY. Anesthetic and analgesic methods for gynecologic brachytherapy:a meta-analysis and systematic review. Brachytherapy.2020 May-Jun;19(3)328-336.
XIII. Viswanathan AN, Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. United States; 2012;11(1):33–46.
XIV. Romano KD, Hill C, Trifiletti DM, Peach MS,Horton BJ, Shah N, Campbell D, Libby B,Showalter TN. High dose-rate tandem and ovoid brachytherapy in cervical cancer:dosimetric predictors of adverse events. Radiat Oncol.2018 Jul16;13(1):129.
XV. Kemıkler G. History of brachytherapy. Turk Onkol Derg. 2019;34(Supp 1):1–10.
XVI. Vicens RA, Rodriguez J, Sheplan L, Mayo C 3rd, Mayo L Jensen C. Brachytherapy in pelvic malignancies:a review for radiologists. Abdom Imaging. 2015 Oct;40(7):2645-59
XVII. Kim H, Rajagopalan MS, Beriwal S. Intracavitary brachytherapy for cervical cancer: a review. J Gynecol Oncol. 2014;25(3):249-257.
XVIII. Balson A, Timotin E, Hunter R, Diamond K.Stability of intracavitary applicator placement for HDR brachytherapy of cervix cancer. J Med Imaging Radiat Sci. 2019;50(3)441-448.
XIX. Yildirim İ. Anesthesia techniques in brachytherapy. Turk Onkol Derg. 2019;34(Supp 1):99–101.
XX. Mahantshetty U, Krishnatry R, Hande V, et al. Comparison of general anesthesia and spinal anesthesia for intracavitary brachytherapy in carcinoma cervix: experience from a tertiary cancer center in India. J Contemp Brachytherapy.2014;6(2):142-146.
XXI. Rathore N, Shukla AK, Bana PC, Jain AK, Rajpurohit VS, Intodia K. The effect of general anaesthesia versus conscious sedation in dosimetric distribution of intracavitary radiotherapy in cervical cancer patients. Int J Res Med Sci. 2017;5(3):940.
XXII. Leong YH, Tan KHS, Choo BA, Koh VY, Tang JIH. Novel anesthetic technique for combined intracavitary and interstitial brachytherapy for cervix cancer in an outpatient setting. J Contemp Brachytherapy. 2017;9(3):236–41.
XXIII. Bhanabhai H, Samant R, E C, Grenier L, Lowry S. Pain assessment during conscious sedation for cervical cancer high-dose-rate brachytherapy. Curr Oncol.